Key points are not available for this paper at this time.
Key Points Noninferiority of anagrelide in comparison with hydroxyurea in WHO-essential thrombocythemia, a phase 3 trial
Share your take
Add a clinician perspective alongside expert commentary.
Gisslinger et al. (2013) studied this question.